GlaxoSmithKline Pharmaceuticals
Market Cap
₹251.2b
Last Updated
2019/10/22 12:34 UTC
Data Sources
Company Financials +
Executive Summary
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines worldwide.
Snowflake
Fundamentals
Flawless balance sheet with outstanding track record.
Similar Companies
Share Price & News
How has GlaxoSmithKline Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
3.5%
500660
4.0%
IN Pharmaceuticals
2.4%
IN Market
1 Year Return
10.0%
500660
-13.9%
IN Pharmaceuticals
8.0%
IN Market
Return vs Industry: 500660 exceeded the Indian Pharmaceuticals industry which returned -13.9% over the past year.
Return vs Market: 500660 exceeded the Indian Market which returned 8% over the past year.
Shareholder returns
| 500660 | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.5% | 4.0% | 2.4% |
| 30 Day | 7.0% | -2.8% | 2.5% |
| 90 Day | 23.5% | 0.7% | 3.6% |
| 1 Year | 11.9%10.0% | -13.1%-13.9% | 10.3%8.0% |
| 3 Year | 5.3%1.0% | -24.6%-26.2% | 22.3%16.0% |
| 5 Year | 18.1%9.7% | -10.2%-12.9% | 42.8%29.3% |
Price Volatility Vs. Market
How volatile is GlaxoSmithKline Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
Is It Time To Sell GlaxoSmithkline Pharmaceuticals Limited (BOM:500660) Based Off Its PE Ratio?Valuation
Is GlaxoSmithKline Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
52.89x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 500660 (₹1482.7) is trading above our estimate of fair value (₹762.36)
Significantly Below Fair Value: 500660 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 500660 is poor value based on its PE Ratio (52.9x) compared to the Pharmaceuticals industry average (15.6x).
PE vs Market: 500660 is poor value based on its PE Ratio (52.9x) compared to the Indian market (13x).
Price to Earnings Growth Ratio
PEG Ratio: 500660 is poor value based on its PEG Ratio (37.3x)
Price to Book Ratio
PB vs Industry: 500660 is overvalued based on its PB Ratio (11.7x) compared to the IN Pharmaceuticals industry average (1.5x).
Next Steps
Future Growth
How is GlaxoSmithKline Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
1.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 500660's forecast earnings growth (1.4% per year) is below the savings rate (7.6%).
Earnings vs Market: 500660's earnings (1.4% per year) are forecast to grow slower than the Indian market (18.4% per year).
High Growth Earnings: 500660's earnings are forecast to grow, but not significantly.
Revenue vs Market: 500660's revenue (13.8% per year) is forecast to grow faster than the Indian market (11.3% per year).
High Growth Revenue: 500660's revenue (13.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 500660's Return on Equity is forecast to be high in 3 years time (29.6%)
Next Steps
Past Performance
How has GlaxoSmithKline Pharmaceuticals performed over the past 5 years?
5.1%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: 500660's earnings have grown by 5.1% per year over the past 5 years.
Accelerating Growth: 500660's earnings growth over the past year (26.9%) exceeds its 5-year average (5.1% per year).
Earnings vs Industry: 500660 earnings growth over the past year (26.9%) exceeded the Pharmaceuticals industry 14.2%.
Return on Equity
High ROE: 500660's Return on Equity (22.2%) is considered high.
Return on Assets
ROA vs Industry: 500660 has a higher Return on Assets than the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: 500660 has significantly improved its Return on Capital Employed over the past 3 years.
Next Steps
Financial Health
How is GlaxoSmithKline Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: 500660's short term assets (₹20.1B) exceeds its short term liabilities (₹14.5B)
Long Term Liabilities: 500660's short term assets (20.1B) exceeds its long term liabilities (3.2B)
Debt to Equity History and Analysis
Debt Level: 500660's debt to equity ratio (0.03%) is considered satisfactory
Reducing Debt: 500660's debt to equity ratio has reduced from 0.2% to 0.03% over the past 5 years.
Debt Coverage: 500660's debt is well covered by operating cash flow (68504%).
Interest Coverage: 500660 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: 500660 has a high level of physical assets or inventory.
Debt Coverage by Assets: 500660's debt is covered by short term assets (assets are 3446.761570x debt).
Next Steps
Dividend
What is GlaxoSmithKline Pharmaceuticals's current dividend yield, its reliability and sustainability?
1.35%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: 500660's dividend (1.35%) is higher than the bottom 25% of dividend payers in the Indian market (0.6%).
High Dividend: 500660's dividend (1.35%) is low compared to the top 25% of dividend payers in the Indian market (2.41%).
Stable Dividend: 500660's dividend payments have been volatile in the past 10 years.
Growing Dividend: 500660's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (71.3%), 500660's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
What is the CEO of GlaxoSmithKline Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
2.3yrs
Average management tenure
CEO
Annaswamy Vaidheesh 0
4.2yrs
Tenure
₹77,985,000
Compensation
Mr. Annaswamy Vaidheesh has been Managing Director, Vice President of South Asia and Executive Director at GlaxoSmithkline Pharmaceuticals Limited since August 3, 2015. Mr. Vaidheesh serves as Director of ...
CEO Compensation Analysis
Compensation vs. Market: Insufficient data to establish whether Annaswamy's total compensation is reasonable compared to companies of similar size in the Indian market.
Compensation vs Earnings: Annaswamy's compensation has increased by more than 20% in the past year.
Management Age and Tenure
2.3yrs
Average Tenure
Experienced Management: 500660's management team is considered experienced (2.3 years average tenure).
Board Age and Tenure
7.3yrs
Average Tenure
66yo
Average Age
Experienced Board: 500660's board of directors are considered experienced (7.3 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Ajay Nadkarni
VP of Administration & Real Estate and Company Secretary
- Tenure: 0yrs
- Compensation: ₹9.18m
Meenakshi Priyam
Executive Vice President of Human Resources
- Tenure: 1.9yrs
Puja Thakur (43yo)
South Asia Finance Director
- Tenure: 1.8yrs
- Compensation: ₹23.62m
Raju Krishnaswamy (53yo)
Executive Director of Technical
- Tenure: 8.2yrs
- Compensation: ₹26.00m
Sumer Dheri
Executive Vice President of Vaccines
- Tenure: 2.5yrs
Annaswamy Vaidheesh
MD, VP of South Asia & Executive Director
- Tenure: 4.2yrs
- Compensation: ₹77.99m
Ransom D'Souza
Vice President of Communications & Government Affairs
- Tenure: 2.5yrs
Anil Iyer
Chief Commercial Officer of Pharmaceuticals
- Tenure: 2.1yrs
Nischal Hindia
Executive Vice President of Legal & Corporate Affairs
- Tenure: 0yrs
S. Balasubramanian
Vice President of Ethics & Compliance
- Tenure: 1yrs
Board Members
Nihal Vijaya Devadas Kaviratne (75yo)
Non-Executive Independent Director
- Tenure: 14.3yrs
- Compensation: ₹2.20m
Anjali Bansal (48yo)
Non-Executive Independent Director
- Tenure: 6.7yrs
- Compensation: ₹2.00m
Damodarannair Sundaram (66yo)
Non-Executive Independent Director
- Tenure: 10.3yrs
- Compensation: ₹2.20m
Subesh Williams (57yo)
Non Executive Director
- Tenure: 2.5yrs
Pradeep Bhide (69yo)
Non-Executive Independent Director
- Tenure: 9yrs
- Compensation: ₹2.10m
Puja Thakur (43yo)
South Asia Finance Director
- Tenure: 1.8yrs
- Compensation: ₹23.62m
Raju Krishnaswamy (53yo)
Executive Director of Technical
- Tenure: 8.2yrs
- Compensation: ₹26.00m
A. Roy (68yo)
Non-Executive Independent Director
- Tenure: 7.9yrs
- Compensation: ₹2.00m
Annaswamy Vaidheesh
MD, VP of South Asia & Executive Director
- Tenure: 4.2yrs
- Compensation: ₹77.99m
Renu Karnad (67yo)
Independent Chairperson
- Tenure: 0.5yrs
Company Information
GlaxoSmithKline Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: GlaxoSmithKline Pharmaceuticals Limited
- Ticker: 500660
- Exchange: BSE
- Founded: 1924
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹251.178b
- Shares outstanding: 169.41m
- Website: https://www.india-pharma.gsk.com
Number of Employees
Location
- GlaxoSmithKline Pharmaceuticals Limited
- GSK House
- Dr. Annie Besant Road
- Mumbai
- Maharashtra
- 400030
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 500660 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Jun 1996 |
| GLAXO | NSEI (National Stock Exchange of India) | Yes | Equity Shares | IN | INR | Jun 1996 |
Biography
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines worldwide. The company offers prescription and non-prescri ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/22 12:34 |
| End of Day Share Price | 2019/10/22 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.